A phase III clinical trial on the immunogenicity of a tetanus vaccine, adsorbed in individuals aged 18 years and above in China
Frontiers in Immunology·
- DOI
- 10.3389/fimmu.2026.1901212
- PMID
- —
- PMCID
- —
- OpenAlex
- W7203770284
- Study type
- Journal article
- Publisher
- Frontiers Media SA
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Findings relate to tetanus vaccination in adults and may inform vaccine evaluation and policy considerations in China for this age group.
Structured evidence summary
Research question
The study evaluates the immunogenicity of an adsorbed tetanus vaccine in adults aged 18 years and above.
Study design
A randomized, double-blinded, positive-controlled clinical trial (Phase III), conducted in Bijie, Guizhou Province, China, with participants randomized 1:1 to experimental or control vaccine arms.
Population and setting
Individuals aged 18 years and above, recruited in Bijie, Guizhou Province, China, with serum samples collected pre-vaccination, 30 days post-vaccination, and at 6 months in the first 240 participants.
Main findings
At 30 days post-vaccination, the experimental vaccine produced a higher antibody GMC (3.205 vs 2.387; P=0.0012) and GMI (35.529 vs 27.604; P=0.0026) than control, with comparable seroconversion (89.07% vs 87.47%; P=0.6149) and seropositivity rates. At 6 months, GMC, seropositivity, and GMI differences were not statistically significant between groups. The authors conclude the experimental vaccine shows good immunogenicity in this age group.
Public-health relevance
Findings relate to tetanus vaccination in adults and may inform vaccine evaluation and policy considerations in China for this age group.
Important limitations
The abstract does not state explicit limitations of the trial. The summary is therefore limited to the supplied single-article abstract and metadata, and decision-grade interpretation would require review of the original paper (including any reported adverse events, long-term follow-up, and subgroup analyses).
GIDS interpretation
The article is discoverable through classifiers for tetanus, vaccination, and treatment in a Chinese setting; it contributes to the vaccine evidence base but, on its own, does not constitute a surveillance signal or outbreak-related finding.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 8 auditable classifier relationships to diseases, places, topics, and study design.